Skip to main content

trade with estonia

Nanordica Medical raises €1.75 million for nanotech wound treatment

Medtech company Nanordica plans to launch innovative wound care products for treating severe wounds. Photo: Nanordica Medical

Estonian medtech company Nanordica Medical has raised €1.75 million to enter the market with first-in-class wound care products curing severe wounds.

The round was led by Estonian fund Specialist VC, with participation from Superangel and Amalfi.

Approximately 100 million patients suffer from chronic wounds such as diabetic foot, venous leg ulcers, and pressure ulcers. The prevalence of these conditions is increasing by 12% annually due to the aging of the population and the rise in underlying diseases such as diabetes and obesity. Annually, 1 million amputations worldwide are caused by these wounds, with most of them being related to poorly managed bacterial infections of wounds.

“We achieved a crucial milestone by demonstrating the safety and efficacy of our advanced wound dressing in patients with the most challenging wounds, diabetic foot ulcers,“ stated co-founder and CEO of Nanordica Medical Olesja Bondarenko. “Our next goal is to get the product to the market and in the hands of patients.”

Patients with infected wounds are typically treated with systemic antibiotics or traditional antibacterials such as silver ion-based dressings or ointments. The Nanordica Medical’s team discovered that by combining copper with silver nanoparticles, bacterial infection can be inactivated up to 8x better compared to traditional antibacterial solutions.

Remarkably, the effect is achieved at very low concentrations, which is important because in this case antibacterial does not harm the patient’s skin cells. A randomized controlled trial of developed wound dressing carried out on 30 patients with infected diabetic foot ulcers showed improved safety and twice as fast healing as one of the most widely used competing silver ion-based wound dressing.

“We achieved a crucial milestone by demonstrating the safety and efficacy of our advanced wound dressing in patients with the most challenging wounds, diabetic foot ulcers.”
Olesja Bondarenko, co-founder and CEO of Nanordica Medical

Nanordica Medical’s team is planning to confirm these exciting results in a larger trial. A multicentered study involving 170 patients with diabetic foot ulcers is planned to start in Q2 2024. This will be one of the largest studies of its kind, paving the path to the inclusion of Nanordica Medical’s wound care products into the reimbursement and treatment guidelines.

“The company’s innovative wound care solution has the potential to positively impact the lives of chronic wound patients across the world,” said Gerri Kodres, the Founder Partner of Specialist VC.

Nanordica Medical’s first product for veterinary use Ravimus Vet was launched in 2023, and the human product is planned to launch in 2025.

Are you interested in trading with Estonia? Enterprise Estonia is providing sourcing service for foreign enterprises. Contact Estonian export advisors or use our free e-consulting service to start trade with Estonia.


ready to trade with estonia?

ready to trade with estonia?

What is it really like to do business in Estonia? How can you benefit from the country’s world-famous e-solutions and unique business culture? What opportunities await you in your sector?

The Trade Estonia team is here to answer all your questions and point you in the right direction.

Request sourcing help